86 related articles for article (PubMed ID: 1964564)
21. Effects of antagonists of 5-hydroxytryptamine on blood pressure in the anesthetised spontaneously hypertensive rat.
Docherty JR; Warnock P
J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S59-61. PubMed ID: 2446073
[TBL] [Abstract][Full Text] [Related]
22. Ketanserin: a possible tool for studying the role of serotonin in hypertension.
Woittiez AJ; Wenting GJ; Man in't Veld AJ; Boomsma F; Schalekamp MA
J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S130-6. PubMed ID: 2412035
[TBL] [Abstract][Full Text] [Related]
23. Diabetic neuropathy is associated with activation of the TNF-alpha system in subjects with type 1 diabetes mellitus.
González-Clemente JM; Mauricio D; Richart C; Broch M; Caixàs A; Megia A; Giménez-Palop O; Simón I; Martínez-Riquelme A; Giménez-Pérez G; Vendrell J
Clin Endocrinol (Oxf); 2005 Nov; 63(5):525-9. PubMed ID: 16268804
[TBL] [Abstract][Full Text] [Related]
24. Contribution of estimated insulin resistance and glucose intolerance to essential hypertension.
Eriksson KF; Lindgärde F
J Intern Med Suppl; 1991; 735():75-83. PubMed ID: 2043225
[TBL] [Abstract][Full Text] [Related]
25. Doxazosin lowers blood pressure and improves insulin responses to a glucose load with no changes in tyrosine kinase activity or insulin binding.
Dominguez LJ; Weinberger MH; Cefalu WT; Jacobs DB; Barbagallo M; Walsh MF; Sowers JR
Am J Hypertens; 1995 May; 8(5 Pt 1):528-32. PubMed ID: 7662232
[TBL] [Abstract][Full Text] [Related]
26. The effect of ketanserin on blood pressure and platelets during cardiopulmonary bypass.
Lichtenthal PR; Wade LD; Rossi EC
Anesth Analg; 1987 Nov; 66(11):1151-4. PubMed ID: 3662060
[TBL] [Abstract][Full Text] [Related]
27. Insulin resistance and urinary excretion of sodium in hypertensive patients with non-insulin dependent diabetes mellitus.
Singh SK; Sarkar D; Agrawal JK
J Assoc Physicians India; 1999 Jul; 47(7):709-11. PubMed ID: 10778592
[TBL] [Abstract][Full Text] [Related]
28. [Clinical application of serotonin antagonists in the treatment of hypertension].
Deguchi F; Saito T; Inagaki Y
Nihon Rinsho; 1989 Sep; 47(9):2058-63. PubMed ID: 2593279
[No Abstract] [Full Text] [Related]
29. Metabolic effects of hydrochlorothiazide and enalapril during treatment of the hypertensive diabetic patient. Enalapril for hypertensive diabetics.
Prince MJ; Stuart CA; Padia M; Bandi Z; Holland OB
Arch Intern Med; 1988 Nov; 148(11):2363-8. PubMed ID: 2847668
[TBL] [Abstract][Full Text] [Related]
30. Effect of converting enzyme inhibitors in hypertensive patients with non-insulin-dependent diabetes mellitus.
Dominguez JR; de la Calle H; Hurtado A; Robles RG; Sancho-Rof J
Postgrad Med J; 1986; 62 Suppl 1():66-8. PubMed ID: 3534865
[TBL] [Abstract][Full Text] [Related]
31. Response of insulin, glucagon, lactate, and nonesterified fatty acids to glucose in visceral obesity with and without NIDDM: relationship to hypertension.
Iannello S; Campione R; Belfiore F
Mol Genet Metab; 1998 Mar; 63(3):214-23. PubMed ID: 9608544
[TBL] [Abstract][Full Text] [Related]
32. Insulin and hypertension. Relationship to obesity and glucose intolerance in Pima Indians.
Saad MF; Knowler WC; Pettitt DJ; Nelson RG; Mott DM; Bennett PH
Diabetes; 1990 Nov; 39(11):1430-5. PubMed ID: 2227116
[TBL] [Abstract][Full Text] [Related]
33. The effect of oral glucose loads on tissue metabolism during angiotensin II receptor and beta-receptor blockade in obese hypertensive subjects.
Boschmann M; Kreuzberg U; Engeli S; Adams F; Franke G; Klaua S; Scholze J; Weidinger G; Luft FC; Sharma AM; Jordan J
Horm Metab Res; 2006 May; 38(5):323-9. PubMed ID: 16718629
[TBL] [Abstract][Full Text] [Related]
34. Ketanserin in the treatment of diabetes-associated hypertension.
Beretta-Piccoli C
Drugs; 1988; 36 Suppl 1():35-43. PubMed ID: 3071461
[TBL] [Abstract][Full Text] [Related]
35. Hemodynamic effects of the anti-hypertensive agent ketanserin in hypertension in man.
Weiss YA; Fournier V; Pannier B; Laurent S; Safar ME
Acta Cardiol; 1987; 42(5):329-37. PubMed ID: 3321806
[TBL] [Abstract][Full Text] [Related]
36. [Disorders of glucose metabolism and hypertension--common etio-pathogenetic factors?].
Ryczak E; Hanzlik J
Kardiol Pol; 1992; 36(2):115-8. PubMed ID: 1583827
[No Abstract] [Full Text] [Related]
37. Clinical and haemodynamic effects of ketanserin in lean and obese hypertensive patients.
Licata G; Scaglione R; Parrinello G; Capuana G; Mazzola G; Lipari R; Castello R; Galantino L
J Int Med Res; 1990; 18(2):112-9. PubMed ID: 2340944
[TBL] [Abstract][Full Text] [Related]
38. Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin.
Vanhoutte P; Amery A; Birkenhäger W; Breckenridge A; Bühler F; Distler A; Dormandy J; Doyle A; Frohlich E; Hansson L
Hypertension; 1988 Feb; 11(2):111-33. PubMed ID: 3277910
[TBL] [Abstract][Full Text] [Related]
39. [The effect of acute administration of ketanserin on the peripheral metabolism of serotonin and hemodynamic indicators in hypertensive patients].
Sebeková K; Raucinová M; Jurecková K
Bratisl Lek Listy; 1990 Nov; 91(11):829-32. PubMed ID: 2265368
[TBL] [Abstract][Full Text] [Related]
40. [Serotonin and its physiological and pathophysiological roles. Ketanserin].
Metelitsa TV
Kardiologiia; 1989 Sep; 29(9):120-5. PubMed ID: 2687555
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
